CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP)
Clinical trials for CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP) explained in plain language.
Never miss a new study
Get alerted when new CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP) trials appear
Sign up with your email to follow new studies for CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug aims to tame rare nerve disorder
Disease control Not yet recruitingThis trial tests a drug called obinutuzumab β in people with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), a condition where the immune system attacks nerves, causing weakness and numbness. Participants receive two intravenous infusions of the drug and are mon…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP)
Phase: PHASE1, PHASE2 • Sponsor: Zhongming Qiu • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New hope for teens with rare nerve disease: drug trial launches
Disease control Not yet recruitingThis study tests a new medicine called empasiprubart in teenagers aged 12 to 17 who have a rare nerve disease called CIDP. The goal is to find the right dose and see if the drug is safe and helps control the disease. Participants will receive the drug for about 27 months and be f…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP)
Phase: PHASE2, PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC